 |
 |
 |
Unlocking EpigeneticsCellCentric has a dominant discovery platform in epigenetics, based on the active management of an unparalleled worldwide network of 25 leading researchers at major Institutions.
CellCentric is uniquely able to identify and prioritize new therapeutic targets for drug discovery as well as epigenetic-related technologies and tools.
|
DiscoveryThe company has multiple small molecule therapeutic discovery programmes across a range of epigenetic enzyme classes. For each programme CellCentric has the benefit of ongoing input from the leading researchers in the space. The company also continues to build a portfolio of screens (cell reprogramming), markers and tools all related to epigenetics. |